LPA Antagonist Compositions for Selective Receptor Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for LPA-associated diseases, such as fibrosis and neuroinflammation, lack effective antagonists to target LPA receptors, leading to inadequate therapeutic options.
Innovation Solution
Development of LPA antagonists, including compounds of Formula I, and pharmaceutical compositions to administer therapeutically effective amounts to treat or prevent LPA-associated diseases.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If LPA antagonists are developed to target LPA receptors, then therapeutic effectiveness for LPA-associated diseases is improved, but device complexity and manufacturing complexity increase due to the need for novel compound structures and formulations
Solution Approach 1:
The LPA antagonist compounds are designed with segmented molecular structures consisting of distinct functional groups (e.g., heterocyclic rings, linker groups, and terminal groups) that can be independently optimized. This segmentation allows for systematic structure-activity relationship studies and facilitates the development of multiple analogs with improved therapeutic properties while managing structural complexity.
Solution Approach 2:
The patent employs parameter changes by systematically varying molecular parameters such as heterocyclic ring types, substituent groups, and molecular weight ranges to optimize the balance between therapeutic effectiveness and manufacturability. This approach enables the identification of compound structures that achieve desired biological activity while maintaining feasibility for pharmaceutical development.
2Reliability
If LPA antagonists are administered at therapeutically effective amounts, then treatment outcomes for fibrosis and neuroinflammation are improved, but loss of substance increases due to metabolic degradation and excretion
Solution Approach 1:
The patent incorporates preliminary protective actions by designing compounds with metabolic stability features, such as deuterium substitution at labile positions and incorporation of metabolically stable heterocyclic rings. These preliminary structural modifications are intended to reduce metabolic degradation before administration, thereby extending half-life and reducing the frequency of dosing required to maintain therapeutic effectiveness.
3Adaptability or versatility
If broad-spectrum LPA receptor antagonism is achieved, then versatility in treating multiple LPA-associated diseases is improved, but object-generated harmful factors increase due to potential off-target effects and side effects
Solution Approach 1:
The patent applies local quality by designing LPA antagonist compounds with specific molecular features that enhance selectivity for LPA receptors over other G-protein coupled receptors. This includes incorporating heterocyclic ring systems and substituent patterns that are tailored to interact preferentially with LPA receptor binding pockets, thereby achieving broad-spectrum antagonism across LPA receptor subtypes while minimizing off-target effects on other receptor families.
Data Source
AI summary
The present disclosure provides LPA antagonists of formula I, as well as pharmaceutical compositions comprising the compounds disclosed herein. Also provided are methods for treating LPA-associated diseases, disorders, and conditions.